Find information on thousands of medical conditions and prescription drugs.

Essential thrombocytosis

Essential thrombocytosis (ET, essential thrombocythemia) is a rare and chronic blood disorder characterized by the overproduction of megakaryocytes (the precursor cell for platelets). Most of these patients will have platelet counts over 600,000 per cubic mm. In some cases this disorder may be progressive, and (very rarely) evolves into acute leukemia or myelofibrosis. more...

Home
Diseases
A
B
C
D
E
Ebola hemorrhagic fever
Ebstein's anomaly
Eclampsia
Ectodermal Dysplasia
Ectopic pregnancy
Ectrodactyly
Edwards syndrome
Ehlers-Danlos syndrome
Ehrlichiosis
Eisoptrophobia
Elective mutism
Electrophobia
Elephantiasis
Ellis-Van Creveld syndrome
Emetophobia
Emphysema
Encephalitis
Encephalitis lethargica
Encephalocele
Encephalomyelitis
Encephalomyelitis, Myalgic
Endocarditis
Endocarditis, infective
Endometriosis
Endomyocardial fibrosis
Enetophobia
Enterobiasis
Eosinophilia-myalgia...
Eosinophilic fasciitis
Eosophobia
Ependymoma
Epicondylitis
Epidermolysis bullosa
Epidermolytic hyperkeratosis
Epididymitis
Epilepsy
Epiphyseal stippling...
Epistaxiophobia
EPP (erythropoietic...
Epstein barr virus...
Equinophobia
Ergophobia
Erysipelas
Erythema multiforme
Erythermalgia
Erythroblastopenia
Erythromelalgia
Erythroplakia
Erythropoietic...
Esophageal atresia
Esophageal varices
Esotropia
Essential hypertension
Essential thrombocythemia
Essential thrombocytopenia
Essential thrombocytosis
Euphobia
Evan's syndrome
Ewing's Sarcoma
Exencephaly
Exophthalmos
Exostoses
Exploding head syndrome
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Pathophysiology

The pathologic basis for this disease is unknown. However, essential thrombosis resembles polycythemia vera in that cells of the megakaryocytic series are more sensitive to growth factors. Platelets derived from the abnormal megakaryocytes do not function properly, which contributes to the clinical features of bleeding and thrombosis.

Recently, in 2005, a mutation in the JAK2 kinase (V617F) was found by multiple research groups (Baxter et al., 2005; Levine et al., 2005) to be associated with essential thrombocytosis. JAK2 is a member of the Janus kinase family. This mutation be helpful in making a diagnosis or as a target for future therapy.

Clinical findings and symptoms

Essential thrombocytosis is the most rare of the myeloproliferative family of diseases. The major symptoms are bleeding and thrombosis. Other symptoms include an enlarged spleen (splenomegaly), epistaxis (nosebleeds) and bleeding from gums and gastrointestinal tract. One characteristic symptom is throbbing and burning of the hands and feet due to the occlusion of small arterioles by platelets (erythromelalgia).

Clinical course

Essential thrombocytosis is a slowly progressing disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic crises. It is diagnosed at a rate of about 2 to 3 per 100,000 individuals and usually affects middle aged to elderly individuals (although it can affect children and young adults). The median survival time for patients with this disorder is 12 to 15 years.

Treatment

In cases where patients have life-threatening complications, the platelet count can be reduced rapidly through platelet apheresis (a procedure that removes platelets from the blood directly). Long-term decreases in platelet counts can reduce bleeding and clotting complications. Common medications include hydroxyurea, interferon-alpha, or anagrelide. Aspirin may also help decrease clotting.

Read more at Wikipedia.org


[List your site here Free!]


Thrombocytosis
From Gale Encyclopedia of Medicine, 4/6/01 by Maureen Haggerty

Definition

Thrombocytosis is a blood disorder, in which the body produces a surplus of platelets (thrombocytes).

Description

Thrombocytosis is an abnormally increased number of platelets in the blood. Platelets are blood cells that stick together, helping blood clot. Thrombocytosis is a condition that may have many causes.

Throbocytosis is classified as one of two types. Secondary thrombocytosis can be traced to another cause, such as inflammation, severe bleeding, iron deficiency, or some cancers. Primary thrombocytosis (or essential thrombocythemia) is a single disease entity, with unique clinical characteristics.

Causes & symptoms

The cause of essential thrombocytosis is unknown.

Secondary thrombocytosis may develop as a result of:

  • Acute hemorrhage or infection
  • Anemia
  • Arthritis and other chronic inflammations
  • Cancer
  • Exercise
  • Iron deficiency
  • Medication
  • Osteoporosis
  • Removal of the spleen (splenectomy)
  • Polycythemia vera (a disorder affecting other red blood cells, as well as platelets)
  • Stress
  • Surgery.

Symptoms

Two of every three patients who have thrombocytosis do not have any symptoms of the disease at the time of diagnosis. Younger patients may remain symptom-free for years.

Enlargement of the spleen is detected in 60% of patients with thrombocytosis. The liver may also be enlarged. As many as half of all patients experience bleeding from the skin, gums, or nose, and 20-50% have some blockage of veins or arteries.

Other symptoms of thrombocytosis include:

  • Bloody stools
  • Bruising
  • Dizziness
  • Headache
  • Hemorrhage
  • Prolonged bleeding after having surgery or after having a tooth pulled
  • Redness or tingling of the hands and feet
  • Weakness. In rare instances, the lymph nodes become enlarged.

The highest platelet counts usually produce the most severe symptoms. Younger patients (especially women) may not have symptoms, even though their platelet counts are very high.

Complications

Complications of thrombocytosis include stroke, heart attack, and formation of blood clots in the arms and legs.

A doctor should be notified whenever bleeding is unexplained or prolonged or the patient develops:

  • Chest or leg pain
  • Confusion
  • Numbness
  • Weakness.

Diagnosis

The patient's symptoms suggest the presence of thrombocytosis. Blood tests confirm the diagnosis.

Bone marrow aspiration (removal of a tissue sample for microscopic examination) may also be performed.

Treatment

The key to treating secondary thrombocytosis is treating the underlying condition.

Any patient who has thrombocytosis should be encouraged not to smoke.

In young people who have no symptoms, this condition can remain stable for many years. These patients should be monitored by a physician, but may not require treatment.

Treatment for patients who do have symptoms focuses on controlling bleeding, preventing the formation of blood clots, and lowering platelet levels. Treatment for secondary thrombocytosis involves treating the condition or disease responsible for excess platelet production.

In 1997, the United States Food and Drug Administration (FDA) approved the use of anagrelide HCI (Agrylin) to reduce elevated platelet counts and decrease the risk of clot formation. Some patients have benefited from the use of hydroxyurea, an anti-cancer drug.

Low doses of aspirin may prevent clotting, but can cause serious hemorrhages.

If drug therapy does not bring platelet counts down to an acceptable level as rapidly as necessary, plateletpheresis may be performed. Usually combined with drug therapy and used primarily in medical emergencies, this procedure consists of:

  • Withdrawing blood from the patient's body
  • Removing platelets from the blood
  • Returning the platelet-depleted blood to the patient.

Prognosis

Many patients with thrombocytosis remain free of complications for long periods. However, some patients may die as a result of blood clots or uncontrolled bleeding.

Prevention

There is no known way to prevent thrombocytosis.

Further Reading

For Your Information

    Books

  • Berkow, Robert, ed. The Merck Manual of Medical Information: Home Edition. Whitehouse Station, NJ: Merck & Co., Inc., 1997.
  • Isselbacher, Kurt, J., et al, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill, Inc., 1994.

    Other

  • FDA Approves Marketing of Agrylin for Thrombocythemia. http://www.plsgroup.com.dg/2114a.htm (31 May 1998).
  • The Merck Manual: Primary Thrombocythemia. http://www.merck.com/!!ux1sK3PObux1sK3POb/pubs/mmanual/html/mjglmjdg.htm (3 June 1998).
  • Primary Thrombocythemia. http://www.healthanswers.com/database/ami/converted/000543.html (31 May 1998).

Gale Encyclopedia of Medicine. Gale Research, 1999.

Return to Essential thrombocytosis
Home Contact Resources Exchange Links ebay